Does the FDA approval cover Complex Partial Seizures and absence seizures together?
Yes, FDA approvals for valproic acid products cover both complex partial seizures and absence seizures. These approvals allow the drug to be used alone or with other medicines for patients with either condition or a mix of both. The approvals also define specific types of absence seizures, such as simple and complex absence.
What the research says
Valproic acid oral solution is approved for monotherapy and adjunctive therapy of complex partial seizures. It is also approved for sole and adjunctive therapy of simple and complex absence seizures 1. This drug is indicated for patients with complex partial seizures that occur either in isolation or in association with other types of seizures 3.
The approval extends to patients with multiple seizure types that include absence seizures. In these cases, valproic acid is used as adjunctive therapy 4. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness without other detectable clinical signs 5. Complex absence is the term used when other signs are also present 2.
Other valproate formulations, such as Depakote Sprinkle Capsules and Valproate Sodium Injection, share these same indications. They are approved for complex partial seizures and simple and complex absence seizures 4. They are also approved for intravenous use in patients who cannot take oral medication temporarily 5.
What to ask your doctor
- Does my specific seizure type match the FDA-approved indications for this medication?
- Am I a candidate for monotherapy or do I need adjunctive therapy based on my seizure history?
- What are the risks for simple versus complex absence seizures with this treatment?
- Are there specific warnings I should know about regarding fetal risks if I am pregnant or planning pregnancy?
This question is drawn from common patient questions about Neurology and answered using cited medical research. We do not provide individualized advice.